Not yet taking people in FrancePhase 1/2
Actinomycin D with venetoclax for acute myeloid leukemia that returned or did not respond
Tests actinomycin D with venetoclax in adults with relapsed or treatment-resistant acute myeloid leukemia.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- Bobigny, Marseille, Nice, Paris, and Villejuif Cedex, FranceSee the 5 sites
- Trial code
- Registry title
- ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 36 people, planned
- Started
- 1 Jun 2026
- Expected to end
- 1 Jun 2029
- Type of study
- Interventional
- Record updated
- 10 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose acute myeloid leukemia (AML) has come back or has not responded to earlier treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory acute myeloid leukemia (AML): the disease came back or did not respond to treatment.
Where in France
- Assistance Publique Hopitaux De ParisBobigny, FranceNot yet recruiting
- Institut Paoli-CalmettesMarseille, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NiceNice, FranceNot yet recruiting
- Assistance Publique Hopitaux de ParisParis, FranceNot yet recruiting
- Institut Gustave RoussyVillejuif Cedex, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Actinomycin D with venetoclax for acute myeloid leukemia that returned or did not respondGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 10 June 2026